EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bioengineered Hybrid Nanovesicles Modulate the Immune Microenvironment with Targeted Drug Delivery for Esophageal Squamous Cell Carcinoma Therapy

Fei Xie, Lulu Feng, Yuting Wang, Chaofan Huang, Chenlong Wang, Chao Luo iD, Li Zhang, Congyong Sun, Qilong Wang iD

ACS Applied Materials & Interfaces · 2026

DOI: 10.1021/acsami.6c14588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Fei Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Central Laboratory, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Northern Jiangsu Institute of Clinical…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Tumor Microenvironment, Paclitaxel, Esophageal Neoplasms. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province, Nanjing Medical University, Graduate Research and Innovation Projects of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combining chemotherapy and immunotherapy shows great promise for treating esophageal squamous cell carcinoma (ESCC), but its effectiveness is hindered by the immunosuppressive tumor environment and challenges in drug delivery. Recent research has focused on cell membrane-coated nanoparticles for targeted drug delivery, leveraging their ability to evade the immune system while selectively targeting tumor cells. In this study, we developed a biomimetic hybrid nanoplatform based on cell membranes to combine molecular chemotherapy and improve the effectiveness of immunochemotherapy in treating ESCC. The nanoplatform is coated with a membrane fusion of activated neutrophils and ESCC cells and loaded with paclitaxel (PTX) and small interfering RNA targeting EFNA1 (siEFNA1), a molecule linked to ESCC metastasis. By exploiting the homologous targeting properties of ESCC cell membranes and the tumor-homing ability of neutrophil membranes, the platform effectively targets ESCC tissues and delivers siEFNA1 and PTX. This allows for a synergistic treatment approach, combining EFNA1 gene silencing with PTX-induced cytotoxicity to target ESCC more effectively. Crucially, the nanoplatform reprograms tumor-associated macrophages from the pro-tumor M2 phenotype to the anti-tumor M1 phenotype while boosting T cell-mediated cytotoxicity and remodeling the immunosuppressive tumor microenvironment. Overall, this strategy presents a promising approach for the targeted treatment of ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaTumor MicroenvironmentPaclitaxelEsophageal NeoplasmsNanoparticlesDrug Delivery SystemsHumansAnimalsCell Line, TumorRNA, Small InterferingMiceDrug CarriersBiomimetic Materials

Stichwörter der Autor:innen

EFNA1esophageal squamous cell carcinomahybrid biomimetic nanovesiclestumor microenvironment remodelingtumor-targeted drug delivery

Substanzen

PaclitaxelRNA, Small InterferingDrug Carriers

Autor:innen und Institutionen

  • Department of Central Laboratory, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Huai'an223300, Jiangsu, China.

ORCID-Profile: Chao Luo, Qilong Wang

Förderung

  • Natural Science Foundation of Jiangsu Province
  • Nanjing Medical University
  • Graduate Research and Innovation Projects of Jiangsu Province
  • Jiangsu Provincial Key Research and Development Program

Zitieren

APA

Xie, F., Feng, L., Wang, Y., Huang, C., Wang, C., Luo, C., Zhang, L., Sun, C., & Wang, Q. (2026). Bioengineered Hybrid Nanovesicles Modulate the Immune Microenvironment with Targeted Drug Delivery for Esophageal Squamous Cell Carcinoma Therapy. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c14588

Vancouver

Xie F, Feng L, Wang Y, Huang C, Wang C, Luo C, et al. Bioengineered Hybrid Nanovesicles Modulate the Immune Microenvironment with Targeted Drug Delivery for Esophageal Squamous Cell Carcinoma Therapy. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c14588

BibTeX
@article{Xie2026,
  author = {Xie, Fei and Feng, Lulu and Wang, Yuting and Huang, Chaofan and Wang, Chenlong and Luo, Chao and Zhang, Li and Sun, Congyong and Wang, Qilong},
  title = {Bioengineered Hybrid Nanovesicles Modulate the Immune Microenvironment with Targeted Drug Delivery for Esophageal Squamous Cell Carcinoma Therapy},
  journal = {ACS Applied Materials & Interfaces},
  year = {2026},
  doi = {10.1021/acsami.6c14588}
}
Kostenlos starten →